Display options
Cite
McNamara MG, Sahebjam S, Mason WP. Anaplastic oligodendroglioma: advances and treatment options. Curr Treat Options Neurol. 2013;15(3):289-301doi: 10.1007/s11940-013-0218-9.
McNamara, M. G., Sahebjam, S., & Mason, W. P. (2013). Anaplastic oligodendroglioma: advances and treatment options. Current treatment options in neurology, 15(3), 289-301. https://doi.org/10.1007/s11940-013-0218-9
McNamara, Mairéad G, et al. "Anaplastic oligodendroglioma: advances and treatment options." Current treatment options in neurology vol. 15,3 (2013): 289-301. doi: https://doi.org/10.1007/s11940-013-0218-9
McNamara MG, Sahebjam S, Mason WP. Anaplastic oligodendroglioma: advances and treatment options. Curr Treat Options Neurol. 2013 Jun;15(3):289-301. doi: 10.1007/s11940-013-0218-9. PMID: 23344797.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Neurol. 2013 Jun;15(3):289-301. doi: 10.1007/s11940-013-0218-9.

Anaplastic oligodendroglioma: advances and treatment options.

Current treatment options in neurology

Mairéad G McNamara, Solmaz Sahebjam, Warren P Mason

Affiliations

  1. Pencer Brain Tumor Centre, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

PMID: 23344797 DOI: 10.1007/s11940-013-0218-9

Abstract

OPINION STATEMENT: The optimal treatment strategy for anaplastic oligodendroglial (AO) tumors is evolving. Molecular profiling of oligodendrogliomas have shown distinctive genetic patterns characterized by combined deletions of chromosome arms 1p and 19q, O(6)-methylguanine methyltransferase (MGMT) methylation, and isocitrate dehydrogenase 1 (IDH1) mutations; they are all prognostic factors for patients with AO. In addition, a strong association has also been found between the CpG island hypermethylation phenotype (CIMP) status and MGMT promoter methylation. Long term follow up data of the Radiation Therapy Oncology Group (RTOG) 9402 and the European Organisation for Research and Treatment of Cancer (EORTC) 26951 studies demonstrate clear evidence that for patients with codeleted 1p19q AO, early chemotherapy with radiation offers a significant improvement in overall survival compared with early radiation, even with salvage chemotherapy at tumor relapse, and thus establishes the 1p19q allelic loss as a predictive marker distinct from tumors without the chromosome change. Radiotherapy alone is no longer considered an adequate treatment for this patient population. In cases with no 1p19q deletion, most neuro-oncologists recommend incorporating radiotherapy into the upfront treatment strategy. However, there are still unanswered questions regarding whether upfront chemotherapy, omitting/deferring radiotherapy, in the desire to avoid late neurocognitive toxicity of radiotherapy should be the initial therapy for AO tumors with codeleted 1p19q, or whether temozolomide, an oral agent with a better toxicity profile, can be substituted for procarbazine, lomustine, and vincristine (PCV). Further studies are warranted and the increasing understanding of molecular pathways involved may lead to more selective therapeutic targets in the future.

References

  1. Neuro Oncol. 2007 Jul;9(3):314-8 - PubMed
  2. J Clin Oncol. 2006 Jun 20;24(18):2707-14 - PubMed
  3. Epilepsy Res. 2011 Mar;94(1-2):39-44 - PubMed
  4. J Clin Oncol. 2013 Jan 20;31(3):337-43 - PubMed
  5. J Clin Oncol. 2002 Apr 15;20(8):2076-84 - PubMed
  6. Nat Rev Cancer. 2004 Apr;4(4):296-307 - PubMed
  7. Neuro Oncol. 2003 Apr;5(2):79-88 - PubMed
  8. Neurology. 2009 May 5;72(18):1601-6 - PubMed
  9. Brain. 2006 Jul;129(Pt 7):1884-91 - PubMed
  10. Neurol Clin. 2007 Nov;25(4):867-90, vii - PubMed
  11. N Engl J Med. 2009 Feb 19;360(8):765-73 - PubMed
  12. Clin Cancer Res. 2011 Nov 15;17(22):7148-55 - PubMed
  13. J Clin Oncol. 2009 Dec 10;27(35):5881-6 - PubMed
  14. Neuro Oncol. 2012 Jan;14(1):109-16 - PubMed
  15. Neuro Oncol. 2011 Nov;13(11):1225-33 - PubMed
  16. Cancer. 2009 Apr 15;115(8):1734-43 - PubMed
  17. Curr Opin Oncol. 2012 Nov;24(6):687-93 - PubMed
  18. Clin Cancer Res. 2004 Jul 1;10(13):4303-6 - PubMed
  19. J Clin Oncol. 1997 Dec;15(12):3427-32 - PubMed
  20. J Clin Oncol. 2009 Dec 10;27(35):5874-80 - PubMed
  21. Lancet Oncol. 2009 May;10(5):459-66 - PubMed
  22. Neurology. 2004 Sep 14;63(5):904-6 - PubMed
  23. Nature. 2009 Dec 10;462(7274):739-44 - PubMed
  24. Radiographics. 2010 Mar;30(2):461-82 - PubMed
  25. J Neurooncol. 2006 Sep;79(3):299-305 - PubMed
  26. Nat Rev Clin Oncol. 2009 Aug;6(8):465-77 - PubMed
  27. Chin Med J (Engl). 2010 Dec;123(24):3566-73 - PubMed
  28. J Clin Oncol. 2011 Dec 1;29(34):4482-90 - PubMed
  29. Neuro Oncol. 2011 Jun;13(6):649-59 - PubMed
  30. Am J Pathol. 2011 Oct;179(4):1638-44 - PubMed
  31. Ann Surg Oncol. 2008 Oct;15(10):2887-93 - PubMed
  32. Cancer. 2004 Feb 15;100(4):807-13 - PubMed
  33. PLoS One. 2010 Sep 03;5(9):e12548 - PubMed
  34. J Clin Oncol. 2001 May 1;19(9):2449-55 - PubMed
  35. Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 - PubMed
  36. J Neurosurg. 2012 Jun;116(6):1172-81 - PubMed
  37. J Clin Oncol. 2006 Jun 20;24(18):2715-22 - PubMed
  38. AJR Am J Roentgenol. 1989 Jul;153(1):141-6 - PubMed
  39. Radiat Oncol. 2011 Dec 21;6:177 - PubMed
  40. Clin Cancer Res. 2010 Mar 1;16(5):1597-604 - PubMed
  41. AJNR Am J Neuroradiol. 2005 Apr;26(4):784-90 - PubMed
  42. Neuro Oncol. 2011 Oct;13(10):1099-106 - PubMed
  43. Neuro Oncol. 2010 May;12(5):490-9 - PubMed
  44. Cancer Res. 2006 Oct 15;66(20):9852-61 - PubMed

Publication Types